Top Markets
#1 Black Phoenix Black Phoenix +166.51%
#2 Islamic Coin Islamic Coin +158.21%
#3 Glidr Glidr +58.56%
#4 Cryptopia Cryptopia +20.30%
#5 DOVU DOVU +19.60%
#6 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.07%
#7 Test Test +11.85%
#8 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +11.57%
#9 MarsCoin MarsCoin +10.95%
#10 stake.link stake.link +8.58%
Coin of the day
Black Phoenix Black Phoenix
Innstillinger
Språk
NORSK
Valuta
USD
Tema
VIA Pharmaceuticals, Inc. VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc.

VIAP
Rangering i aksjer #41780
VIA Pharmaceuticals, Inc. is an emerging biotechnology company primarily... VIA Pharmaceuticals, Inc. is an emerging biotechnology company primarily focused on discovering and advancing therapeutic compounds for cardiovascular and metabolic disorders. The firm is building a portfolio of small-molecule drug candidates designed to tackle the root causes of these health issues, such as vascular inflammation, elevated cholesterol and triglyceride levels, and insulin resistance or diabetes. Notable candidates in their development pipeline include: VIA-3196: A liver-specific thyroid hormone receptor (THR) beta agonist, poised for Phase 1 clinical studies. This drug aims to mitigate dyslipidemia, addressing high LDL cholesterol, elevated triglycerides, and Lp(a) levels. A Diacylglycerol Acyl Transferase 1 (DGAT1) inhibitor: Currently in preclinical development for treating type 2 diabetes, with promising potential for weight management and other lipid disorders. VIA-2291: A 5-Lipoxygenase inhibitor that has successfully completed its third Phase 2 clinical trial. Its purpose is to target atherosclerotic plaque, a significant contributor to heart attacks, strokes, and various other vascular diseases. VIA Pharmaceuticals has also forged two research, development, and commercialization agreements with Hoffman-LaRoche Inc. and Hoffman-LaRoche Ltd. These collaborations pertain to their THR beta agonist program and several compounds from their preclinical DGAT1 metabolic disorders initiative. Established in 2004, the company's headquarters are located in San Francisco, California.
Aksjekurs
$0.0005
Sist synkronisert: 2026-08-11
Markedsverdi
$10.28K
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel VIA Pharmaceuticals, Inc. (VIAP)

Kategori

Healthcare
Inntekter for VIA Pharmaceuticals, Inc. (VIAP)
Inntekter i Aug 2026 TTM: 0
Ifølge de nyeste økonomiske rapportene til VIA Pharmaceuticals, Inc. er selskapets nåværende inntekter (TTM) 0. I 2026 hadde selskapet inntekter på 0 lik inntektene i 2026, som var 0. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for VIA Pharmaceuticals, Inc. fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
 $2.54B -
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
 - -
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
 - -
FR
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
 - -
IT
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
 $830.81M -
US